
SEATTLE — Trudhesa was effective in treating migraines of varying severity, a speaker said at the 2022 American Academy of Neurology annual meeting.
“In my clinical practice, a lot of patients end up delaying their treatment [with Trudhesa (dihydroergotamine mesylate, Impel NeuroPharma)] and it doesn’t always work,” Sheena K. Aurora, MD, a neurologist and vice president of medical affairs at Impel NeuroPharma, said. “It’s always recommended that the patients take their treatment as early as possible.”